Abstract
Metastases are the most common brain tumors especially in adults. Although they are generally considered a single disease entity which is universally fatal in patients with advanced cancer, brain metastases are remarkably heterogeneous both clinically and pathologically. As members of the multidisciplinary clinical team for the diagnosis and management of metastatic brain tumors, pathologists must be familiar not only with clinicopathologic features of brain metastases but also with any characteristic and clinically significant molecular findings. We discuss here the epidemiology, general gross and microscopic features of brain metastases with emphasis on how to differentiate them from primary brain tumors using immunohistochemistry (e.g., for identification of the primary site and differential diagnosis), and unique pathologic patterns of brain metastases (namely, dural metastasis, leptomeningeal carcinomatosis, miliary metastasis, “intravascular carcinomatosis”, and tumor-to-tumor metastasis) with their clinical and radiological characteristics. We specifically address metastatic breast and non-small cell lung cancers which are the two most commonly encountered in daily practice, with emphasis on the molecular alterations related to therapy and their clinicopathologic significance.
Similar content being viewed by others
References
Nayak L, Lee EQ, Wen PY (2012) Epidemiology of brain metastases. Curr Oncol Rep 14:48–54
Iuchi T, Shingyoji M, Itakura M et al (2014) Frequency of brain metastases in non-small-cell lung cancer, and their association with epidermal growth factor receptor mutations. Int J Clin Oncol 20:674–679
Berghoff AS, Bago-Horvath Z et al (2013) Impact of Her-2-targeted therapy n overall survival in patients with Her-2 positive metastatic breast cancer. Breast J 19:149–155
Dummer R, Goldinger SM, Turtschi CP et al (2014) Vemurafenib in patients with BRAF V600 mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur J Cancer 50:611–621
Beierwaltes WH, Lieberman LM, Varma VM, Counsell RE (1968) Visualizing human malignant melanoma and metastases. Use of chloroquine analog tagged with iodine 125. JAMA 206:97–102
DeAngelis LM (1994) Management of brain metastases. Cancer Invest 12:156–165
Nussbaum ES, Djalilian HR, Cho KH, Hall WA (1996) Brain metastases. Histology, multiplicity, surgery, and survival. Cancer 78:1781–1788
Lagerwaard FJ, Levendag PC, Nowak PJ et al (1999) Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys 43:795–803
Long GV, Menzies AM, Nagrial AM et al (2011) Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 29:1239–1246
Skibber JM, Soong SJ, Austin L et al (1996) Cranial irradiation after surgical excision of brain metastases in melanoma patients. Ann Surg Oncol 3:118–123
Kolomainen DF, Larkin JM, Badran M et al (2002) Epithelial ovarian cancer metastasizing to the brain: a late manifestation of the disease with an increasing incidence. J Clin Oncol 20:982–986
Tremont-Lukats IW, Bobustuc G, Lagos GK et al (2003) Brain metastasis from prostate carcinoma: the M. D. Anderson Cancer Center experience. Cancer 98:363–368
Hjiyiannakis P, Jefferies S, Harmer CL (1996) Brain metastases in patients with differentiated thyroid carcinoma. Clin Oncol (R. Coll Radiol) 8:327–330
Fox BD, Patel A, Suki D, Rao G (2009) Surgical management of metastatic sarcoma to the brain. J Neurosurg 110:181–186
Kebudi R, Ayan I, Görgün O et al (2005) Brain metastasis in pediatric extracranial solid tumors: survey and literature review. J Neurooncol 71:43–48
Curless RG, Toledano SR, Ragheb J et al (2002) Hematogenous brain metastasis in children. Pediatr Neurol 26:219–221
Parker GD, Hamsberger HR (1991) Clinical-radiologic issues in perineural tumor spread of malignant diseases of the extracranial head and neck. Radiographics 11:383–399
Porter AT, David M (2007) Palliative care for bone, spinal cord, brain and liver metastases. In: Gunderson LL, Tepper JE (eds) Clinical radiation oncology. Elsevier, Philadelphia, pp 437–455
Narayana A, Liebel SA (2004) Primary and metastatic brain tumors. In: Liebel SA, Phillips TL (eds) Textbook of radiation oncology. Elsevier, Philadelphia, pp 463–495
Nonaka H, Akima M, Hatori T et al (2003) The microvascular of the cerebral white matter: arteries of the subcortical white matter. J Neuropathol Exp Neurol 62:154–161
Hwang TL, Close TP, Grego JM et al (1996) Predilection of brain metastasis in gray and white matter junction and vascular border zones. Cancer 77:1551–1555
Fowler BZ, Crocker IR, Johnstone PAS (2005) Perineural spread of cutaneous malignancy to the brain. A review of the literature and five patients treated with stereotactic radiotherapy. Cancer 103:2143–2153
Pekmezci M, Perry A (2013) Neuropathology of brain metastasis. Surg Neurol Int 4(Suppl 4):S245–S255
Tacha D, Qi W, Ra S et al (2015) A newly developed mouse monoclonal SOX10 antibody is a highly sensitive and specific marker for malignant melanoma, including spindle cell and desmoplastic melanomas. Arch Pathol Lab Med 139:530–536
Carney EM, Banerjee P, Ellis CL et al (2011) PAX2(−)/PAX8(−)/inhibin A(+) immunoprofile in hemangioblastoma: a helpful combination in the differential diagnosis with metastatic clear cell renal cell carcinoma to the central nervous system. Am J Surg Pathol 35:362–367
Kawakami F, Takei H (2015) Central nervous system metastasis. In: Rivera A, Takei H (eds) Advances in surgical pathology. Brain cancer. Wolter Kluwer, Philadelphia, pp 189–196
Posner JB, Chernik NL (1978) Intracranial metastases from systemic cancer. In: Schoenberg BS (ed) Advances in neurology. Raven Press, New York, pp 579–592
Takakura K, Sano K, Hojo S, Hirano A (1982) Metastatic tumors of the central nervous system. Igaku-shoin, Tokyo
Nayak L, Abrey LE, Iwamoto FM (2009) Intracranial dural metastases. Cancer 115:1947–1953
Laigle-Donadey F, Taillibert S, Mokhtari K et al (2005) Dural metastases. J Neurooncol 75:57–61
Caputi F, Lamaida E, Gazzeri R (1999) Acute subdural hematoma and pachymeningitis carcinomatosa: case report. Rev Neurol (Paris) 155:383–385
Turner DM, Graf CJ (1982) Nontraumatic subdural hematoma secondary to dural metastasis: case report and review of the literature. Neurosurgery 11:678–680
Bucci MN, Farhat SM (1986) Metastatic adenocarcinoma of the prostate as a cause of subdural hematoma. J Urol 135:803–804
Russell DS, Cairns H (1934) Subdural false membrane or haematoma (pachymeningitis interna haemorrhagica) in carcinomatosis and sarcomatosis of the dura mater. Brain 57:32–48
Pace A, Fabi A (2006) Chemotherapy in neoplastic meningitis. Crit Rev Oncol Hematol 60:194–200
Chowdhary S, Chamberlain M (2005) Leptomeningeal metastases: current concepts and management guidelines. J Natl Compr Cancer Netw 3:693–703
Glass JP, Melamed M, Chernik NL, Posner JB (1979) Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology 29:1369–1375
Jaeckle KA (2006) Neoplastic meningitis from systemic malignancies: diagnosis, prognosis and treatment. Semin Oncol 33:312–323
Wasserstrom WR, Glass JP, Posner JB (1982) Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 49:759–772
Kaplan JG, DeSouza TG, Farkash A et al (1990) Leptomeningeal metastases: comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias. J Neurooncol 9:225–229
Amer MH, Al-Sarraf M, Baker LH, Valtkevicius VK (1978) Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival. Cancer 42:660–668
Niwińska A, Rudnicka H, Murawska M (2013) Breast cancer leptomeningeal metastasis: propensity of breast cancer subtypes for leptomeninges and the analysis of factors influencing survival. Med Oncol 30:408
Yap HY, Yap BS, Tashima CK, DiStefano A, Blumenschein GR (1978) Meningeal carcinomatosis in breast cancer. Cancer 42:283–286
Chamberlain MC (2005) Neoplastic meningitis. J Clin Oncol 23:3605–3613
Subira D, Simo M, Illan J et al (2015) Diagnostic and prognostic significance of flow cytometry immunophenotyping in patients with leptomeningeal carcinomatosis. Clin Exp Metastasis 32:383–391
Garson JA, Coakham HB, Kemshead JT et al (1985) The role of monoclonal antibodies in brain tumour diagnosis and cerebrospinal fluid (CSF) cytology. J Neurooncol 3:165–171
Hovestadt A, Henzen-Logmans SC, Vecht CJ (1990) Immunohistochemical analysis of the cerebrospinal fluid for carcinomatous and lymphomatous leptomeningitis. Br J Cancer 62:653–654
Boogerd W, Vroom TM, van Heerde P et al (1988) CSF cytology versus immunohistochemistry in meningeal carcinomatosis. J Neurol Neurosurg Psychiatry 51:142–145
Madow L, Alpers BJ (1951) Encephalitic form of metastatic carcinoma. AMA Arch Neurol Psychiatry 65:161–173
Ogawa M, Kurahishi K, Ebina A et al (2007) Miliary brain metastasis presenting with dementia: progression pattern of cancer metastases in the cerebral cortex. Neuropathology 27:390–395
Iguchi Y, Mano K, Goto Y et al (2007) Miliary brain metastases from adenocarcinoma of the lung: MR imaging findings with clinical and post-mortem histopathologic correlation. Neuroradiology 49:35–39
Kahveci R, Gurer B, Kaygusuz G, Sekerci Z (2012) Miliary brain metastases from occult lung adenocarcinoma: radiologic and histopathologic confirmation. J Neurosci Rural Pract 3:386–389
Hutchings M, Weller RO (1986) Anatomical relationships of the pia mater to cerebral blood vessels in man. J Neurosurg 65:316–325
Zhang ET, Inman CBE, Weller RO (1990) Interrelationships of the pia mater and the perivascular (Virchow–Robin) spaces in the human cerebrum. J Anat 170:111–123
Takei H, Rouah E, Barrios R (2015) Intravascular carcinomatosis of central nervous system due to metastatic inflammatory breast cancer: a case report. Neuropathology 35:456–461
Campbell LV, Gilbert E, Chamberlein CR, Watne AL (1968) Metastases of cancer to cancer. Cancer 22:635–643
Pamphlett R (1984) Carcinoma metastasis to meningioma. J Neurol Neurosurg Psychiatry 47:561–563
Erdogan H, Aydin MV, Tasdemiroglu E (2014) Tumor-to-tumor metastasis of the central nervous system. Turk Neurosurg 24:151–162
Hamazaki S, Nakashima H, Matsumoto K et al (2001) Metastasis of renal cell carcinoma to central nervous system hemangioblastoma in two patients with von Hippel-Lindau disease. Pathol Int 51:948–953
Mottolese C, Stan H, Giordano F et al (2001) Metastasis of clear-cell renal carcinoma to cerebellar hemangioblastoma in von Hippel-Lindau disease: rare or not investigated. Acta Neurochir (Wien) 143:1059–1063
Chambers PW, Davis RL, Blanding JD, Buck FS (1980) Metastases to primary intracranial meningiomas and neurilemmomas. Arch Pathol Lab Med 104:350–354
Li Z, Lu J, Zhao Y, Guo H (2011) The retrospective analysis of the frequency of EGFR mutations and efficacy of gefitinib in NSCLC patients with brain metastases. J Clin Oncol 29:e18065
Rangachari D, Yamaguchi N, VanderLaan PA et al (2015) Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer 88:108–111
Zhang J, Yu J, Sun X, Meng X (2014) Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of central nerve system metastases from non-small cell lung cancer. Cancer Lett 351:6–12
Camidge DR, Bang YJ, Kwak EL (2012) Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase I study. Lancet Oncol 13:1011–1019
Otterson GA, Riely GJ, Shaw AT (2012) Clinical characteristics of ALK + NSCLC patients treated with crizotinib beyond disease progression: potential implications for management. Proc Am Soc Clin Oncol 30(Suppl):abstract 7600
Guerin A, Sasane M, Zhang J et al (2015) Brain metastasis in patients with ALK+ non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden. J Med Econ 18:321–322
Gainor JF, Ignatius S-H, Logan J, Borges LF, Shaw AT (2013) The central nervous system as a sanctuary site in ALK-positive non-small cell lung cancer. J Thorac Oncol 8:1570–1573
Weil RJ, Palmieri DC, Bronder JL, Stark AM, Steeg PS (2005) Breast cancer metastasis to the central nervous system. Am J Pathol 167:913–920
Kennecke H, Yerushalmi R, Woods R et al (2012) Metastatic behavior of breast cancer subtype. J Clin Oncol 28:3271–3277
Gil-Gil MJ, Martinez-Garcia M, Sierra A et al (2014) Breast cancer brain metastases: a review of the literature and a current multidisciplinary management guideline. Clin Transl Oncol 16:436–446
Shen Q, Sahin AA, Hess KR et al (2015) Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis. Oncologist 20:466–473
Van Poznak C, Somerfield MR, Bast RC et al (2015) Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 33:2695–2704
Template for reporting results of biomarker testing of specimens from patients with carcinoma of the breast. CAP www.cap.org/apps/docs/committees/…/her2_faqs.pdf. Accessed 25 Aug 2015
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Takei, H., Rouah, E. & Ishida, Y. Brain metastasis: clinical characteristics, pathological findings and molecular subtyping for therapeutic implications. Brain Tumor Pathol 33, 1–12 (2016). https://doi.org/10.1007/s10014-015-0235-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10014-015-0235-3